Polar Capital’s Q32 Bio QTTB Stock Holding History

Polar Capital’s Portfolio QTTB Stock Details QTTB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-5,556	Closed	-$1.96M	–	309
2019 Q2	$1.96M	Hold	5,556	–	–	0.02%	257
2019 Q1	$2.77M	Hold	5,556	–	–	0.03%	233
2018 Q4	$2.24M	Buy	+5,556	New	+$2.1M	0.02%	231

Other funds holding QTTB

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Polar Capital's QTTB Position: Q3 2019 in Review

Polar Capital sold out of Q32 Bio (QTTB) in Q3 2019, closing a stake of 5,556 shares — an estimated $1.96M sold.

Polar Capital first reported a position in QTTB in Q4 2018 and held it in 3 quarters. The position peaked at $2.77M in Q1 2019. 80 funds tracked by Wall St. Rank hold QTTB as of Q3 2019.

Polar Capital reported no remaining Q32 Bio position as of Q3 2019 after selling out during the quarter.
Polar Capital sold 5,556 Q32 Bio shares in Q3 2019, an estimated $1.96M.
Polar Capital first reported a position in Q32 Bio in Q4 2018 and held it in 3 quarters.
Polar Capital's Q32 Bio position peaked at $2.77M in Q1 2019.
80 funds tracked by Wall St. Rank held Q32 Bio as of Q3 2019.

Based on Polar Capital's 13F filing for Q3 2019, filed 14 Nov 2019.